Mallinckrodt Pharmaceuticals and Endo are in talks over a potential merger worth about $7 billion, according to a report from ...

Unlocking manufacturing capacity will be key for Legend Biotech and Johnson and Johnson in achieving their goal of reaching ...

Trump admin's FDA medical product review units remain protected from cuts, while Marty Makary awaits confirmation as ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...

Ascletis' ASC47 shows 1.7% weight loss vs. placebo in Phase 1b trial, Vivace gets a $35M Series D for VT3989, and Harbour BioMed launches obesity startup Élancé Therapeutics.

Merck has opened a new vaccine manufacturing plant at its existing site in Durham, NC, which will make a shot that is an ...

Bristol Myers Squibb will acquire its CAR-T cell therapy collaborator 2seventy bio for $286 million in cash, the companies ...

Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to ...

Merck convinced a federal judge to toss claims alleging that it failed to properly warn patients of potential risks related ...

Beam Therapeutics said its experimental gene editing treatment helped lower levels of mutant proteins and increase levels of ...

For­mer Ae­tion CEO Car­olyn Mag­ill has joined dig­i­tal health ven­ture firm De­fine Ven­tures as a ven­ture part­ner. It’s ...

Novo Nordisk’s CagriSema demonstrated weight loss of 15.7% in patients with both obesity and type 2 diabetes who took the ...